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Abstract
Background: Epidemiological studies associate consumption of whole grain foods, including breads, with reduced 
cardiovascular disease (CVD) risk; however, few studies have compared wheat whole grains with wheat refined grains.
Methods: This study investigated effects of 6-week consumption of whole grain wheat sourdough bread in 
comparison to white bread on fasting serum lipids in normoglycemic/normoinsulinemic (NGI; n = 14) and 
hyperglycemic/hyperinsulinemic (HGI; n = 14) adults. The influence of single-nucleotide polymorphisms, 3 within the 
APOE gene (E2, E3, E4) and 2 within the hepatic lipase gene promoter (LIPC -514C>T, LIPC -250G>A) were considered.
Results: At baseline, HGI participants had significantly higher body weight, waist circumference, body fat, and fasted 
glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), glucagon, triacylglycerols (TAG) and 
TAG:HDL-cholesterol, compared to NGI participants; however, none of these in addition to none of the other serum 
lipids, differed between bread treatments, within either participant group. For participants with the APOE E3/E3 
genotype, LDL-cholesterol (P = 0.02) increased in the NGI group (n = 7), and TAG (P = 0.03) and TAG:HDL-cholesterol (P 
= 0.04) increased in the HGI group (n = 10), following consumption of whole grain wheat sourdough compared to 
white bread.
Conclusions: In summary, 6-week consumption of whole grain wheat sourdough bread did not significantly modulate 
serum lipids in NGI or HGI adults; however, it significantly increased LDL-cholesterol, TAG and TAG:HDL-cholesterol in 
participants with the APOE E3/E3 genotype. These data add to limited literature comparing wheat whole grains to 
wheat refined grains on CVD risk and highlight the need to consider genetic variation in relation to lipoprotein lipid 
content and CVD risk.
Background
Epidemiological studies consistently associate consump-
tion of whole grain foods, including whole grain breads,
with reduced cardiovascular disease (CVD) risk [1-6] and
CVD related co-morbidities [7-10]. Whole grains have
the potential to reduce CVD risk through improvements
in circulating lipids including decreased total-cholesterol,
LDL-cholesterol and triacylglycerols (TAG), and
increased HDL-cholesterol [11]. Although mechanisms
for these effects are unclear, whole grain bioactive con-
stituents such as dietary fiber, trace minerals, vitamins,
lignans and phytochemicals may be potential contribu-
tors [12-14].
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Research suggests that processing techniques that pre-
pare the whole grain for digestion and absorption may
not remove their bioactive constituents [15], therefore
rationalizing the potential for breads made from whole
grains to reduce CVD risk. Potential properties of whole
grain breads such as sourdough fermentation [16] and
large grain particle size [13] may provide additional
health benefits including increased mineral bioavailabil-
ity and improved postprandial glycemic response [17-20].
In contrast, refined grains found in white breads, contain
more available carbohydrate and less dietary fiber, both of
which may increase postprandial glycemia and circulat-
ing TAG leading to increased CVD risk [11,21].
Despite epidemiological evidence to support a role for
whole grains in reducing CVD risk [1-6], results of inter-
vention studies are inconsistent. Although intervention
studies have replaced refined with whole grain foods [22-
25], those that measured serum lipids did not attribute
changes to the whole grains [22,24]. However, these
investigations had study design limitations such as inclu-
sion of whole grain foods produced from milled flour
[22], use of a hypocaloric diet [24] and dependence on
participants to self-select whole grain foods [24]. Further,
although wheat was the dominant grain included [22-25],
it is not known whether effects were due to wheat or non-
wheat whole grains. Giacco et al. [26] addressed this by
using only wheat products in a 3-week intervention of
wholemeal wheat compared to refined wheat foods,
which significantly decreased fasting total- and LDL-cho-
lesterol in healthy adults. As well, other studies that have
used less comprehensive interventions have demon-
strated improved serum lipids following consumption of
powdered wheat fibre [27]; high-protein, high-fibre
wheat flakes [28]; and wheat whole grain and wheat bran
cereal [29]. Potential mechanisms behind these effects
include decreased glycemia, insulinemia and lipoprotein
particles [30]. Studies that have focused on wheat breads
h a v e  e i t h e r  n o t  m e as u r e d  [ 3 1 ]  o r  f o u n d  n o  s i gn i f i ca n t
effect [32,33] on serum lipids, prompting the need for
more whole grain wheat bread interventions.
In addition to the use of traditional CVD biomarkers to
investigate the impact of whole grains, it is of value to
consider individual genetic variation [34,35]. Single-
nucleotide polymorphisms (SNPs), particularly the e mis-
sense mutations of the APOE gene [36] and those of the
hepatic lipase gene promoter (LIPC) [37], are reflective of
varying circulating lipid profiles and thus warrant study
in relation to CVD risk assessment. In addition to dyslipi-
demia, these SNPs may also help identify additional iso-
lated or combined CVD risk factors such as obesity and
dysglycemia.
The purpose of the current study was to address the
knowledge gap in whole grain wheat intervention studies
by investigating effects of whole grain and refined wheat
bread consumption on CVD risk while considering the
influence of genetic variation. The primary objective of
this dietary intervention was to determine the response
to 6-week consumption of whole grain wheat sourdough
bread in comparison to white bread, on fasted serum lip-
ids and apolipoproteins, in healthy men and postmeno-
pausal women of low and high levels of CVD risk. A
secondary objective was to consider the influences of
APOE  and  LIPC  polymorphisms on the serum lipid
responses to the bread treatments.
Methods
Participants
Men and postmenopausal women (defined as absence of
menstruation ≥ 1 y) aged 43-70 y, were recruited using
posters and newspaper advertisements. Participants were
initially screened using an eligibility questionnaire and
excluded if they reported the presence of any serious
medical condition (i.e. CVD, diabetes, cancer, hepatic
disease, renal disease), frequent alcohol consumption (≥ 2
drinks.d-1), use of lipid-lowering medication, use of hor-
mone replacement therapy, use of daily aspirin, major
body weight changes (> 5% of usual body weight within
the last 6 months), current or planned attempts at trying
to lose or gain weight, plans to alter their habitual life-
style, elite athletic training or an allergy to gluten. Poten-
tial participants meeting these criteria then underwent an
oral glucose tolerance test (OGTT) of 75 g dextrose (Tru-
tol 75, NERL Diagnostics, RI, USA) to rule out diabetes
(based on fasted and 2-h glucose) and to determine fasted
and 2-h whole blood glucose and serum insulin. Potential
participants were then considered eligible if they met the
inclusion criteria of 1 of 2 groups representing different
levels of CVD risk. Inclusion criteria for the normoglyce-
mic/normoinsulinemic (NGI) group were: BMI 19-25
kg·m-2 and/or waist circumference < 102 cm for men and
< 88 cm for women, and all of the following: normal
fasted glucose (plasma glucose < 6.1 mmol·L-1), normal
glucose tolerance (2-h post-OGTT plasma glucose < 7.8
mmol·L-1), and normal fasted insulin (serum insulin < 90
pmol·L-1). Inclusion criteria for the hyperglycemic/hyper-
insulinemic (HGI) group were: BMI > 29.9 kg·m-2 and/or
waist circumference ≥ 102 cm for men and ≥ 88 cm for
women, and one of the following: fasted hyperglycemia
(plasma glucose 6.1-6.9 mmol·L-1), impaired glucose tol-
erance (2-h post-OGTT plasma glucose 7.8-11.0 mmol·L-
1), and/or fasted hyperinsulinemia (serum insulin > 90
pmol·L-1). A total of 28 men and postmenopausal women
were included in the study (n = 14 NGI; 10 male, 4 female
and n = 14 HGI; 10 male, 4 female). A sample size of 28
participants was estimated to be adequate for detection
of a 10% change in fasting total-cholesterol using varia-
tion in accordance with the literature [22,24,26], an alphaTucker et al. Nutrition & Metabolism 2010, 7:37
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of 0.05, a power of 0.80 and 2-sided testing. The study
was approved by the Human Research Ethics Board of the
University of Guelph and all participants provided writ-
ten consent.
Study design and treatment breads
The study utilized a randomized crossover design in
which participants added 2 commercially available breads
(whole grain wheat sourdough and white) to their habit-
ual diets for 6 weeks each, separated by 4-5 week washout
period. The whole grain wheat sourdough bread con-
sisted predominantly of whole grain wheat flour (37% dry
weight) and also contained other ingredients including
non-wheat grains (18% dry weight: whole grain spelt and
rye flours, brown flax seeds, rolled oats, cracked soy, yel-
low flax seeds, millet seeds, malted barley flour, brown
rice flour, millet flour, durum semolina and organic sour-
dough made from natural bacterial culture, whole grain
spelt and rye flours).
The quantity of treatment breads provided was deter-
mined to correspond with 65% of the daily grain serving
recommendation of Canada's Food Guide (CFG) [38],
which, based on a bread slice of 35 g, equated to 136.5-
163.8 g bread·d-1 (6-7 grain servings·d-1) for women and
159.3-182.0 g bread·d-1 (7-8 grain servings/d) for men.
The daily number of slices of treatment bread provided
was then calculated using the average grain serving CFG
recommendation based on bread weight divided by the
weight of the treatment bread slices (25 g/slice for whole
grain wheat sourdough bread and 37.5 g/slice for white
bread). Therefore, the number of slices provided to
women and men, respectively, was 6 and 7 for whole
grain wheat sourdough bread and 4 and 5 for white bread.
The nutritional composition of each daily amount of
bread was then calculated accordingly (Table 1).
Daily portions of the treatment breads were packaged
into freezer bags and immediately distributed or frozen
until distributed to participants in 2 week supplies on
study d 1, 14 and 28. Participants were instructed to con-
sume their treatment bread in place of other bread prod-
ucts (e.g. bagels, pitas, dinner rolls) or carbohydrate-rich
foods (e.g. pasta, rice). Participants continued their habit-
ual diet with the exception of avoiding natural health
products (except for multi-vitamin/mineral supplements
which were permitted).
Data collection and sample analysis
Participants reported to the laboratory on d 0, 1, 14, 28,
42 and 43, of each treatment period. For each set of 3-d
before a fasted blood sample, participants were
instructed to avoid caffeine, alcohol and strenuous exer-
cise. On d -1, 0, 41 and 42, participants were instructed to
consume a standard meal by 8 pm consisting of a single-
serving lasagna, apple or orange juice box, and chocolate
or vanilla pudding or chocolate granola bar, after which,
only water was permitted.
Body measurements
Height was measured on d 0 using a standard measuring
tape or a stadiometer (Seca Mod. 220, Germany)
(depended on availability but consistent within a partici-
pant), with participants standing with their feet together
and back and heels against the wall or the vertical bar of
the stadiometer.
Body weight was measured on d 0, 1, 14, 28, 42 and 43
of each treatment period using an analog (Ohaus I-10,
VA, USA), household (Hydro Scale, Taiwan) or balance
beam (Seca Mod. 220, Germany) scale (depended on
availability but consistent within a participant) with par-
ticipants wearing a light shirt, no shoes and having empty
pockets. BMI was calculated as body weight (kg)/height
(m2).
Waist circumference was measured using a standard
measuring tape on d 0, 1, 42 and 43 of each treatment
period between the top of the iliac crest (hip bones) and
the bottom of the rib cage with participants wearing a
light shirt.
Body composition was measured on d 0, 1, 42 and 43 of
each treatment period using bioelectrical impedance
analysis (BIA) (BodyStat™ 1500, BodyStat Ltd., MI, USA)
with participants resting in a supine position. Partici-
pants were instructed to consume at least 2 glasses of
water the evening before their BIA measurement to
increase the measurement's accuracy.
Diastolic and systolic blood pressure was measured in
duplicate using a blood pressure monitor (Dinamap™ Plus
Vital Signs Monitor, Johnson & Johnson Medical Inc., FL,
USA) on d 0, 1, 42 and 43 of each treatment period, after
the participants were rested for 5 min.
Food records
Three-d food records were completed on d -3 to -1, 12 to
14, 30 to 32 and 39 to 41 of each treatment period. Partic-
ipants were provided food record sheets with space to
indicate time of food or drink consumption, amount and
a detailed description. Food records were analyzed for 3-
d average intakes of energy, protein, carbohydrate, dietary
fiber, total fat, SFA, MUFA, PUFA and cholesterol using
the ESHA Food Analysis program (Version 9.8.0, Salem,
OR, USA).
Glycemic parameters
Fasted venous blood samples were collected on d 0, 1, 42
and 43 of each treatment period for analysis of whole
blood glucose, serum insulin and plasma glucagon. Data
were averaged from d 0 and 1, and from d 42 and 43. To
reduce the effects of inter-assay variability, all samplesTucker et al. Nutrition & Metabolism 2010, 7:37
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from the same participant were analyzed in the same
assay.
Whole blood for glucose was prepared from blood col-
lected into sodium heparin coated collection tubes (BD
Vacutainer(tm), Becton, Dickinson and Company, NJ,
USA), mixed thoroughly and kept on ice until measure-
ment in duplicate using a glucose auto-analyzer (YSI2300
Stat Plus, YSI Inc., Yellow Springs, OH, USA). Intra-assay
variability for glucose was 1.3%.
Serum for insulin was processed from blood collected
into anti-coagulant-free collection tubes (Beckman
Allegra® Beckman Coulter Inc., CA, USA), left to clot at
room temperature for 30 min, centrifuged at 1500 × g for
15 min at 5°C, aliquoted and frozen at -20°C until analy-
sis. Serum insulin was analyzed using a single antibody-
coated tube RIA with 125I-labeled hormone (Coat-A-
Count, Siemens Medical Solution Diagnostics, CA, USA).
Inter- and intra-assay variability for insulin was 1.4% and
1.9%, respectively.
Plasma for glucagon was prepared from blood collected
into K2 EDTA collection tubes (BD Vacutainer™) with 6
μL of dipeptidyl peptidase IV inhibitor (Millipore, MO,
USA). Within 1 min of collection, 90 μL of bovine lung
aprotinin (Sigma Aldrich, MO, USA) was added and
mixed thoroughly. Collection tubes were centrifuged 5-
15 min later at 1000 × g for 10 min at 5°C and plasma was
frozen at -20°C until analysis. Plasma glucagon was ana-
lyzed using a double antibody RIA with 125I-labeled hor-
mone (Millipore, MO, USA). Inter- and intra-assay
variability for glucagon was 3.7% and 3.6%, respectively.
The homeostasis model assessment of insulin resis-
tance (HOMA-IR) was calculated as fasted whole blood
glucose (mmol·L-1) × fasted serum insulin (pmol·L-1)/
22.5.
Serum lipids and apolipoproteins
Fasted venous blood samples were collected on d 0 and
43 of each treatment period for analysis of serum lipids
and apolipoproteins into anti-coagulant-free collection
tubes, left to clot at room temperature for 30 min, centri-
fuged at 1500 × g for 15 min at 5°C and frozen at -20°C
until analysis. Serum total-cholesterol, HDL-cholesterol
and TAG were measured at Guelph General Hospital
(Guelph, ON, Canada) using an auto-analyzer (Synchron
CX systems, Beckman Coulter, Mississauga, ON, Can-
ada) with all samples from each participant in the same
batch. LDL-cholesterol was calculated using the Friede-
wald equation when TAG ≤ 4.52 mmol·L-1) [39] and non-
HDL-cholesterol was calculated as total-cholesterol
minus HDL-cholesterol. Calculations were also per-
formed for the ratios of total-cholesterol:HDL-choles-
terol, LDL-cholesterol:HDL-cholesterol, TAG:HDL-
cholesterol and non-HDL-cholesterol:HDL-cholesterol.
Inter- and intra-assay variability, respectively, was 1.6%
and 5.7% for total-cholesterol, 7.3% and 8.4% for HDL-
cholesterol, and 8.2% and 4.8% for TAG.
Serum apolipoprotein B and apolipoprotein AI were
analyzed at the Lipid Analytical Laboratory (Toronto,
ON, Canada) by end-point nephelometry [40] using a
Behring Nephelometer ProSpec(r) System Assay Loader
(Dade Behring Inc., Mississauga, ON, Canada) with all
Table 1: Daily amount and composition of study treatment breads1
Whole grain wheat sourdough bread White bread
Male Female Male Female
Number of slices 7 6 5 4
Total bread amount (g) 175.0 150.0 187.5 150.0
Energy (kJ) 1553 1331 1947 1557
T o t a l  c a r b o h y d r a t e  ( g ) 6 4 . 85 5 . 58 5 . 56 8 . 4
S t a r c h  ( g ) 5 0 . 94 3 . 77 4 . 15 9 . 3
T o t a l  s u g a r s  ( g ) 4 . 9 04 . 2 01 0 . 98 . 7 0
T o t a l  d i e t a r y  f i b e r  ( g ) 1 4 . 91 2 . 88 . 4 46 . 7 5
S o l u b l e  f i b e r  ( g ) 1 . 0 50 . 9 00 . 5 60 . 4 5
I n s o l u b l e  f i b e r  ( g ) 1 3 . 81 1 . 97 . 8 86 . 3 0
P r o t e i n  ( g ) 1 9 . 61 6 . 81 6 . 71 3 . 4
F a t  ( g ) 3 . 6 83 . 1 56 . 1 94 . 9 5
1Data were analyzed by Industrial Laboratories of Canada (Mississauga, Ontario, Canada).Tucker et al. Nutrition & Metabolism 2010, 7:37
http://www.nutritionandmetabolism.com/content/7/1/37
Page 5 of 13
samples from each participant in the same batch, and the
apolipoprotein B/apolipoprotein AI ratio was calculated.
Inter- and intra-assay variability, respectively, was 5.0%
and 6.1% for apolipoprotein B, and 10.8% and 5.8% for
apolipoprotein AI.
Polymorphism genotyping
Venous whole blood for genotyping was collected into
sodium heparin coated collection tubes, mixed thor-
oughly and refrigerated at 4°C for 1-2 d before analysis.
Whole blood samples were collected on d 42 of the last
treatment period for 14 of the participants and within 3
months of completion of the study for 13 of the partici-
pants (sample was not collected from 1 participant (male
NGI)).
DNA was extracted from fresh heparinized whole
blood using a QIAamp DNA Blood Mini Kit (Qiagen,
CA, USA). Genomic DNA was then amplified using an
Illustra GenomiPhi V2 DNA Amplification Kit (GE
Healthcare, Baie d'Urfe, QC, Canada). The e missense
SNPs of the APOE gene (E2, E3, E4) were characterized
by methods described by Wood et al. [41]. Described
briefly, following PCR amplification of the 244 bp frag-
ment of the APOE gene, variants were identified by HhaI
digestion, separated on an 18% polyacrylamide gel and
visualized with SYBR green (Invitrogen, ON, Canada)
staining. LIPC -514C>T genotyping was performed using
methods described by Couture et al. [37]. Described
briefly, following the amplification of the 285 bp fragment
of the LIPC gene, variants were identified using NlaIII
digestion, separated on a 6% polyacrylamide gel and visu-
alized with SYBR green staining. LIPC -250G>A genotyp-
ing was performed using methods described by van't
Hooft et al. [42]. Described briefly, following the PCR
amplification of the 710 bp fragment of the LIPC gene
promoter, variants were identified using DraI digestion,
separated on a 1.5% agarose gel and visualized with ethid-
ium bromide staining.
Study diary
A daily study diary was kept during each treatment
period in which participants were instructed to record
how and when they consumed their treatment bread,
physical activity, illness and medication use.
Statistical analyses
The Statistical Analysis System, version 9.1 (SAS Insti-
tute, Cary, NC, USA) was used for all statistical analyses
with significance set at P ≤ 0.05 and unless indicated oth-
erwise, all data are presented mean ± SEM. Examination
of all data using box plots, stem leaf diagrams and normal
probability plots revealed that serum insulin, plasma glu-
cagon, HOMA-IR, serum TAG and TAG:HDL-choles-
terol were not normally distributed and were therefore
logarithmically transformed prior to statistical analyses
and presented as geometric mean (95% CI).
Comparisons of participant baseline characteristics
(body weight, BMI, body fat, waist circumference, blood
pressure, whole blood glucose, serum insulin, HOMA-IR,
plasma glucagon, serum lipids) between the NGI and
HGI group were completed using unpaired Student's t-
tests.
Comparison of serum lipids among identified geno-
types (E2/E3, E3/E3 and E3/E4; -514CC and -514CT; -
250GG and -250GA) within the NGI and HGI groups
were completed using ANOVA, controlling for genotype,
followed by the Tukey's test for multiple comparisons.
The effect of treatment on the average of d 42 and 43
values for body measurements (body weight, BMI, waist
circumference, body fat) and glycemic parameters (fasted
whole blood glucose, fasted serum insulin, HOMA-IR,
fasted plasma glucagon) was determined within the NGI
and HGI groups separately using repeated measures anal-
ysis of covariance (ANCOVA), controlling for partici-
pant, treatment period and treatment and including the
average of d 0 and 1 values as a covariate, followed by the
Tukey's test for multiple comparisons.
The effect of treatment on energy and nutrient (pro-
tein, carbohydrate, dietary fiber, total fat, SFA, MUFA,
PUFA, cholesterol) intakes was determined within the
NGI and HGI groups separately using unpaired Student's
t-tests.
The effect of treatment on serum lipids at d 43 was
determined within the NGI and HGI group separately
using repeated measures ANCOVA, controlling for par-
ticipant, treatment period and treatment and including d
1 values as a covariate, followed by the Tukey's test for
multiple comparisons. The influence of genotype (E2/E3,
E3/E3 and E3/E4; -514CC and -514CT; -250GG and -
250GA) on the effect of treatment on serum lipids at d 43
was determined within the NGI and HGI group sepa-
rately using repeated measures ANCOVA, controlling for
participant, treatment period and treatment and includ-
ing d 1 values as a covariate, followed by the Tukey's test
for multiple comparisons.
Results
Participant characteristics
The 28 participants (n = 14 NGI, n = 14 HGI) who started
the study completed both treatments with the exception
of 1 female (HGI) who did not complete the whole grain
wheat sourdough bread treatment due to personal rea-
sons. Participants were Caucasian (n = 27) and African
Canadian (n = 1, male HGI). At study entry, participants
within the HGI group had significantly higher body
weight, BMI, waist circumference, percent body fat, and
fasted concentrations of whole blood glucose, serum
insulin, HOMA-IR, plasma glucagon, serum TAG andTucker et al. Nutrition & Metabolism 2010, 7:37
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serum TAG:HDL-cholesterol, when compared to partici-
pants within the NGI group (Table 2).
Polymorphism genotyping
For the APOE polymorphisms, the identified proportions
were 0.19 for the E2/E3 genotype (n = 2 NGI, n = 3 HGI);
0.63 for the E3/E3 genotype (n = 7 NGI, n = 10 HGI) and
0.19 for the E3/E4 genotype (n = 4 NGI, n = 1 HGI).
There were no APOE E2/E2 or E4/E4 homozygous partic-
ipants identified. For the LIPC polymorphisms (-514C>T
and -250G>A), the identified participants and propor-
tions were the same (due to complete linkage disequilib-
rium) at 0.74 for the common homozygous (CC and GG)
genotypes (n = 8 NGI, n = 12 HGI) and 0.26 for the rare
heterozygous (CT and GA) genotypes (n = 5 NGI, n = 2
HGI). There were no LIPC TT or AA homozygous partic-
ipants identified. Additionally, there were no significant
differences in any baseline serum lipids between the gen-
otypes for either the APOE or LIPC polymorphisms (data
not shown).
Body measurements and glycemic parameters
Body measurements, including BMI, body fat, waist cir-
cumference and systolic and diastolic blood pressure, did
not significantly differ at either day 1 or day 43 between
the whole grain wheat sourdough and white bread treat-
ments, within either the NGI or HGI group (data not
shown). Body weight data also did not significantly differ
Table 2: Baseline characteristics of NGI and HGI adults1, 2
NGI HGI P-value group effect3
n1 4 1 4
Gender (male (n)/female (n)) 10/4 10/4
Age (y) 53.1 ± 1.61 57.4 ± 1.97 0.10
Height (m) 1.73 ± 0.11 1.73 ± 0.09 0.97
Body weight (kg) 79.4 ± 3.66 107.4 ± 5.10 0.0001
BMI (kg·m-2) 26.5 ± 0.78 35.7 ± 1.51 < 0.0001
Waist circumference (cm) 93.4 ± 2.18 116.3 ± 2.96 < 0.0001
Body fat (%) 27.8 ± 2.03 36.0 ± 2.14 0.01
Systolic blood pressure (mmHg)4 116.9 ± 4.07 126.3 ± 3.16 0.08
Diastolic blood pressure (mmHg)4 66.0 ± 2.11 68.8 ± 2.60 0.45
Whole blood glucose (mmol·L-1) 4.47 ± 0.11 5.04 ± 0.10 0.0007
Serum insulin (pmol·L-1)5 30.9 (26.6, 35.8) 93.8 (80.7, 108.9) < 0.0001
HOMA-IR5 0.85 (0.73, 0.98) 3.00 (2.60, 3.46) < 0.0001
Plasma glucagon (ng·L-1)5 56.7 (48.1, 66.9) 71.0 (60.4, 83.5) 0.05
Serum total-chol (mmol·L-1) 5.10 ± 0.21 4.87 ± 0.26 0.50
Serum HDL-chol (mmol·L-1) 1.28 ± 0.10 1.06 ± 0.08 0.11
Serum LDL-chol (mmol·L-1)5 3.30 ± 0.18 2.98 ± 0.25 0.31
Serum TAG (mmol·L-1)5 1.06 (0.84, 1.34) 1.63 (1.22, 2.18) 0.02
Serum non-HDL-chol (mmol·L-1) 3.81 ± 0.21 3.81 ± 0.28 0.98
Total-chol:HDL-chol 4.26 ± 0.32 4.97 ± 0.46 0.22
LDL-chol:HDL-chol 2.82 ± 0.27 3.06 ± 0.32 0.57
TAG:HDL-chol5 0.87 (0.62, 1.21) 1.60 (1.09, 2.36) 0.01
Non-HDL-chol:HDL-chol 3.26 ± 0.32 3.97 ± 0.46 0.22
Apolipoprotein B (g·L-1) 0.92 ± 0.06 0.96 ± 0.07 0.65
Apolipoprotein AI (g·L-1) 1.54 ± 0.07 1.42 ± 0.06 0.21
Apolipoprotein B: Apolipoprotein AI 0.62 ± 0.05 0.70 ± 0.07 0.34
1Values are mean ± SEM unless otherwise indicated. Abbreviations: chol: cholesterol.
2All plasma and serum endpoints were collected in the fasted state.
3P-values for differences between NGI and HGI groups at study entry using ANOVA.
4Within the HGI group, n = 12 for whole grain wheat sourdough bread and n = 13 for white bread.
5Data were log-transformed prior to statistical analysis and presented as geometric mean (95% CI).Tucker et al. Nutrition & Metabolism 2010, 7:37
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between whole grain wheat sourdough and white bread
treatments at either day 1 (NGI: 80.1 ± 3.64 kg and 79.4 ±
3.61 kg, respectively; HGI: 106.6 ± 5.85 kg and 106.9 ±
5.04 kg, respectively) or day 43 (NGI: 79.6 ± 3.61 kg and
79.3 ± 3.67 kg, respectively; HGI: 106.0 ± 5.71 kg and
106.4 ± 4.99 kg, respectively). Similarly, glycemic parame-
ters, including fasted whole blood glucose, serum insulin,
HOMA-IR and plasma glucagon, did not significantly dif-
fer at either day 1 or day 43 between the whole grain
wheat sourdough and white bread treatments, within
either the NGI or HGI group (data not shown).
Energy and nutrient intakes
Daily intakes of energy, carbohydrate, protein, total fat,
SFA, MUFA, PUFA or cholesterol did not significantly
differ between the 3-d period before the start of each
treatment, within either the NGI or HGI group (data not
shown). During the study, intakes of dietary fiber (within
the NGI and HGI group) and MUFA (within the NGI
group) were significantly greater during the whole grain
wheat sourdough compared to the white bread treatment
(Table 3). There were no significant differences in the
intakes of energy or other nutrients (protein, total carbo-
hydrate, total fat, SFA, PUFA, cholesterol) between bread
treatments, within either the NGI or HGI group (Table
3).
Serum lipids and apolipoproteins
Fasted serum lipids, including total-cholesterol, HDL-
cholesterol, LDL-cholesterol, TAG, apolipoprotein B and
apolipoprotein AI, did not significantly differ between the
whole grain wheat sourdough and white bread treat-
ments, within either the NGI or HGI group (Table 4).
Similarly, lipid ratios, including total-cholesterol:HDL-
cholesterol, LDL-cholesterol:HDL-cholesterol,
TAG:HDL-cholesterol, non-HDL-cholesterol:HDL-cho-
lesterol and apolipoprotein B:apolipoprotein AI, did not
significantly differ between the whole grain wheat sour-
dough and white bread treatments, within either the NGI
or HGI group (data not shown).
The effect of whole grain wheat sourdough bread con-
sumption on serum lipids was significantly influenced by
presence of the APOE E3/E3 genotype. Within the NGI
participants, LDL-cholesterol significantly increased fol-
lowing consumption of whole grain wheat sourdough
compared to white bread in participants with the APOE
E3/E3 genotype (Table 5) but not in participants with the
E2/E3 or E3/E4 genotypes (data not shown). Within the
HGI participants, TAG and TAG:HDL-cholesterol signif-
icantly increased following consumption of whole grain
wheat sourdough compared to white bread in partici-
pants with the APOE E3/E3 genotype (Table 5) but not in
participants with the E2/E3 or E3/E4 genotypes (data not
shown). There were no significant differences in any
other serum lipids or lipid ratios between the whole grain
wheat sourdough and white bread treatments in partici-
pants with the APOE E3/E3 genotype, within either the
NGI or HGI group (Table 5). Similarly, there were no sig-
nificant differences in serum lipids or lipid ratios between
the whole grain wheat sourdough and white bread treat-
ments in participants with the LIPC -514C>T or LIPC -
250G>A genotypes, within either the NGI or HGI group
(data not shown).
Discussion
The current study measured serum lipids in response to
consumption of whole grain wheat sourdough bread
compared to white bread for 6 weeks each, using a ran-
domized crossover design. The study concurrently inves-
tigated 2 groups of participants that significantly differed
in CVD risk and also considered genetic variation in
response to the bread treatments through identification
of gene polymorphisms related to CVD risk.
Although body measurements and glycemic endpoints
were significantly different between the NGI and HGI
groups at study entry, which established their metabolic
distinction, they did not significantly differ between
treatments, within either group. The lack of change in
body measurements (body weight, BMI, body fat, waist
circumference) suggests that participants followed their
habitual diet and physical activity routines throughout
the study to minimize potential confounding effects.
Noteworthy is that the lack of change in body weight
between treatment periods is consistent with previous
similar studies [26-28,32,33]. As expected though, during
the study, consumption of the high-fiber whole grain
wheat sourdough bread caused an increase in dietary
fiber intake within both participant groups relative to the
white bread. The whole grain wheat sourdough bread
also caused an increase in MUFA intake, only within the
NGI group, which is less obviously explained, but given
the lack of significant difference in energy or other
macronutrients, may be due to variation in food record
analysis. Of note, participants were not counselled on the
macronutrient distribution of their diet and the results
show that their macronutrient intake distribution was
comparable to that reported in Canadian nutrition sur-
veys [43].
Fasting serum lipids, apolipoproteins and related ratios
were not significantly affected by 6-week consumption of
whole grain wheat sourdough bread (12.8-14.9 g dietary
fiber/d; Table 1) in comparison to white bread (6.75-8.44
g dietary fiber/d; Table 1), within either the NGI or HGI
group. These findings are consistent with a study by Jen-
kins et al. [32] in which serum total-, LDL- and HDL-cho-
lesterol were not significantly affected by 4-week
consumption of 2 high-wheat fiber breads (25 g dietary
fiber/d) of varying wheat bran particle size compared toTucker et al. Nutrition & Metabolism 2010, 7:37
http://www.nutritionandmetabolism.com/content/7/1/37
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low-wheat fiber bread (6 g dietary fiber/d) in hypercho-
lesterolemic adults, although the same study found that
serum TAG were significantly reduced by both high-
wheat fiber breads. Other related studies have also found
significant lipid changes including reduced total-choles-
terol:HDL-cholesterol following 2-week consumption of
high-protein wheat flakes (21 g dietary fiber/d) in healthy
adults [28], reduced total-cholesterol following 3-week
consumption of wheat bran (13 g dietary fiber/d) and
whole grain wheat (5.7 g dietary fiber/d) cereal in hyperc-
holesterolemic adults [29] and reduced total- and LDL-
cholesterol following 3-week consumption of wholemeal
c o m p a r e d  t o  r e f i n e d  w h e a t  f o o d  p r o d u c t s  i n  h e a l t h y
adults [26]. The most comparable participant group stud-
ied in relation to the current study's HGI participants is
that of Sabovic et al. [27] who studied adults with dysmet-
abolic cardiovascular syndrome (defined by obesity,
impaired glucose tolerance, dyslipidemia and arterial
hypertension) and found significantly decreased total-,
LDL- and HDL-cholesterol following 5-week consump-
tion of wheat fiber supplements (21 g dietary fiber/d). It is
possible that if the current study's HGI participants had
more metabolic dysregularities like the Sabovic et al. [27]
participants, the wheat fiber in the whole grain wheat
sourdough bread may have significantly influenced serum
lipids. Overall, the inconsistent lipid results among the
few whole grain wheat intervention studies completed to
date highlights the need for further research.
The gene polymorphisms considered in the current
study included 3 of the APOE gene (E2, E3 and E4) and 2
of the LIPC gene (-514C>T and -250G>A). Genotyping
results revealed proportions consistent with the general
Table 3: Effect of 6-wk whole grain wheat sourdough bread consumption on energy and nutrient intakes in NGI and HGI 
adults1
Whole grain wheat 
sourdough bread
White bread P-value treatment effect2
n
NGI 14 14
HGI 13 14
Energy (kJ)
NGI 9726 ± 480 9986 ± 510 0.71
HGI 10140 ± 625 10634 ± 506 0.54
Protein (g)
NGI 93.1 ± 5.18 87.9 ± 4.41 0.45
HGI 104.1 ± 8.66 108.0 ± 5.84 0.71
Total carbohydrate (g)
NGI 291.9 ± 22.3 323.6 ± 23.0 0.33
HGI 284.2 ± 20.1 306.9 ± 18.7 0.41
Dietary fiber (g)
NGI 31.2 ± 2.04 22.0 ± 1.88 0.003
HGI 29.6 ± 2.13 20.2 ± 1.62 0.002
Total fat (g)
NGI 89.6 ± 5.00 83.9 ± 3.62 0.37
HGI 93.5 ± 7.40 95.5 ± 5.16 0.83
MUFA (g)
NGI 20.4 ± 1.57 16.6 ± 0.99 0.05
HGI 25.5 ± 2.67 26.6 ± 2.48 0.75
Cholesterol (mg)
NGI 228.7 ± 28.6 227.7 ± 15.6 0.98
HGI 326.5 ± 34.7 372.7 ± 31.7 0.33
1Values are mean ± SEM.
2P-value for treatment effect comparison of energy and nutrient intakes averaged over 3 sets of 3-d food records (d -3 to -1, 12 to 14, 30 to 
32) within each treatment period using unpaired Student's t-test.Tucker et al. Nutrition & Metabolism 2010, 7:37
http://www.nutritionandmetabolism.com/content/7/1/37
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Caucasian population for all 5 SNPs [34,41,44]. When the
influence of having the common APOE E3/E3 genotype
was considered, results showed that the whole grain
wheat sourdough bread significantly increased LDL-cho-
lesterol in NGI participants (n = 7) and significantly
increased TAG and TAG:HDL-cholesterol in HGI partic-
ipants (n = 10). Although no other whole grain wheat
intervention study has considered genetic variation,
many other studies have examined the influence of APOE
genotypes, particularly since the APOE  allele variation
can account for approximately 7% of the inter-individual
variation in total- and LDL-cholesterol [44]. As reviewed
by Ordovas et al. [45], APOE genotypes have primarily
been studied in relation to dietary interventions of fat
[46,47], cholesterol [48,49] and dietary fiber [50,51]. Most
related to the current study, oat bran intervention studies
of 2- [51] and 4- [50] week durations have found signifi-
cantly greater reductions in total- and LDL-cholesterol in
those with the APOE E3/E3 genotype [50] and in those
who are APOE E2 allele carriers [51], in comparison with
wheat bran. The inconsistency of these results with those
of the current study and the limited number of related
studies confirm the need for continued consideration of
nutrigenetics in dietary fiber-related intervention studies.
The finding of increased LDL-cholesterol following
consumption of whole grain wheat sourdough bread in
Table 4: Effect of 6-wk whole grain wheat sourdough bread consumption on fasting serum lipids in NGI and HGI adults1
Whole grain wheat sourdough bread White bread P-value treatment effect2
Day 1 Day 43 Day 1 Day 43
n
N G I 1 41 41 4 1 4
H G I 1 31 31 4 1 4
Total-chol (mmol·L-1)
NGI 5.04 ± 0.22 5.17 ± 0.18 5.19 ± 0.21 5.00 ± 0.19 0.06
HGI 4.77 ± 0.27 5.07 ± 0.29 4.96 ± 0.28 5.07 ± 0.31 0.71
HDL-chol (mmol·L-1)
NGI 1.33 ± 0.13 1.33 ± 0.11 1.29 ± 0.10 1.28 ± 0.10 0.38
HGI 1.06 ± 0.09 1.05 ± 0.09 1.08 ± 0.09 1.10 ± 0.09 0.59
LDL-chol (mmol·L-1)
NGI 3.23 ± 0.19 3.31 ± 0.17 3.39 ± 0.18 3.16 ± 0.14 0.24
HGI3 2.85 ± 0.27 3.08 ± 0.29 3.06 ± 0.26 3.13 ± 0.30 0.86
TAG (mmol·L-1)4
NGI 1.01 (0.80, 1.27) 1.08 (0.85, 1.36) 1.02 (0.77, 1.35) 1.07 (0.78, 1.49) 0.94
HGI 1.64 (1.16, 2.32) 1.87 (1.30, 2.68) 1.68 (1.23, 2.29) 1.71 (1.25, 2.34) 0.75
Non-HDL-chol (mmol·L-1)
NGI 3.71 ± 0.22 3.84 ± 0.19 3.90 ± 0.22 3.72 ± 0.20 0.11
HGI 3.71 ± 0.30 4.02 ± 0.33 3.88 ± 0.31 3.97 ± 0.33 0.49
Apolipoprotein B (g·L-1)
NGI 0.89 ± 0.06 0.93 ± 0.05 0.94 ± 0.06 0.90 ± 0.05 0.28
HGI 0.94 ± 0.07 0.99 ± 0.07 0.97 ± 0.07 0.97 ± 0.07 0.43
Apolipoprotein AI (g·L-1)
NGI 1.55 ± 0.08 1.56 ± 0.07 1.50 ± 0.06 1.56 ± 0.06 0.63
HGI 1.40 ± 0.06 1.42 ± 0.06 1.41 ± 0.05 1.47 ± 0.06 0.39
1Values are mean ± SEM unless otherwise indicated. Abbreviations: chol: cholesterol.
2P-value for treatment effect comparison between day 43 values of white and whole grain sourdough breads within the NGI and HGI groups, 
using repeated measures ANCOVA controlling for participant, treatment period and treatment and including d 1 values as a covariate, 
followed by the Tukey's test for multiple comparisons.
3Within the HGI group, n = 12 for whole grain wheat sourdough bread (Days 1 and 43) and n = 13 for white bread (Days 1 and 43).
4Data were log-transformed prior to statistical analysis and presented as geometric mean (95% CI).Tucker et al. Nutrition & Metabolism 2010, 7:37
http://www.nutritionandmetabolism.com/content/7/1/37
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Table 5: Effect of 6-wk whole grain whole wheat sourdough bread consumption on fasting serum lipids in NGI and HGI 
adults with the APOE E3/E3 genotype1
APOE E3/E3
Whole grain wheat sourdough bread White bread P-value treatment effect2
Day 1 Day 43 Day 1 Day 43
n
N G I 7777
HGI 9 9 10 10
Total-chol (mmol·L-1)
NGI 5.02 ± 0.30 5.18 ± 0.29 5.06 ± 0.38 4.93 ± 0.34 0.15
HGI 4.84 ± 0.31 5.34 ± 0.29 5.09 ± 0.28 5.22 ± 0.33 0.15
HDL-chol (mmol·L-1)
NGI 1.26 ± 0.15 1.23 ± 0.13 1.14 ± 0.10 1.14 ± 0.13 0.62
HGI 1.05 ± 0.13 1.05 ± 0.13 1.08 ± 0.13 1.12 ± 0.12 0.49
LDL-chol (mmol·L-1)
NGI 3.22 ± 0.28 3.39 ± 0.29 3.40 ± 0.34 3.14 ± 0.26 0.02
HGI3 2.84 ± 0.31 3.20 ± 0.35 3.10 ± 0.26 3.23 ± 0.35 0.45
TAG (mmol·L-1)4
NGI 1.10
(0.73, 1.67)
1.17
(0.79, 1.72)
1.07
(0.69, 1.67)
1.24
(0.68, 2.27)
0.40
HGI 1.83
(1.17, 2.86)
2.31
(1.52, 3.51)
1.93
(1.37, 2.73)
1.83
(1.26, 2.66)
0.03
Non-HDL-chol (mmol·L-1)
NGI 3.76 ± 0.35 3.95 ± 0.36 3.92 ± 0.41 3.79 ± 0.38 0.08
HGI 3.79 ± 0.33 4.29 ± 0.35 4.01 ± 0.31 4.10 ± 0.37 0.07
Total-chol:HDL-chol
NGI 4.30 ± 0.49 4.52 ± 0.49 4.66 ± 0.47 4.63 ± 0.50 0.24
HGI 5.14 ± 0.63 5.76 ± 0.75 5.23 ± 0.59 5.17 ± 0.61 0.10
LDL-chol:HDL-chol
NGI 2.82 ± 0.40 3.01 ± 0.41 3.15 ± 0.39 2.99 ± 0.39 0.06
HGI3 3.01 ± 0.40 3.18 ± 0.49 3.04 ± 0.38 3.03 ± 0.43 0.16
TAG:HDL-chol4
NGI 0.91
(0.48, 1.71)
0.98
(0.56, 1.73)
0.96
(0.53, 1.74)
1.13
(0.52, 2.45)
0.48
HGI 1.85
(0.97, 3.53)
2.33
(1.20, 4.53)
1.89
(1.11, 3.23)
1.72
(0.96, 3.09)
0.04
Non-HDL-chol:HDL-chol
NGI 3.30 ± 0.49 3.52 ± 0.49 3.66 ± 0.47 3.63 ± 0.50 0.24
HGI 4.14 ± 0.63 4.76 ± 0.75 4.23 ± 0.59 4.17 ± 0.61 0.06
Apolipoprotein B (g·L-1)
NGI 0.92 ± 0.09 0.95 ± 0.09 0.94 ± 0.10 0.91 ± 0.08 0.15
HGI 0.98 ± 0.08 1.06 ± 0.08 1.00 ± 0.07 1.01 ± 0.08 0.15
Apolipoprotein AI (g·L-1)
NGI 1.50 ± 0.06 1.50 ± 0.07 1.41 ± 0.05 1.47 ± 0.09 0.24Tucker et al. Nutrition & Metabolism 2010, 7:37
http://www.nutritionandmetabolism.com/content/7/1/37
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the NGI participants with the APOE E3/E3 genotype was
unexpected and may be explained by a shift in utilization
of glucose as a substrate for hepatic acetyl-CoA produc-
tion. Although it is possible that the glucose sensing tran-
scription factor carbohydrate response element binding
protein [52] may have influenced LDL-cholesterol in the
APOE E3/E3 sample within the NGI group, this hypothe-
sis was not tested in the current study.
The findings of increased TAG and TAG:HDL-choles-
terol following consumption of the whole grain wheat
sourdough bread in the HGI participants with the APOE
E3/E3 genotype was also unexpected. Given that APOE
genotypes are not commonly associated with effects on
TAG or HDL-cholesterol, clear explanations for these
findings are unconfirmed. Recently, however, Wood et al.
[41] demonstrated an interaction between the APOE and
LIPC genes in their effect on plasma TAG in the general
population. Therefore, a larger sample size in the current
study may have allowed for detection of an interaction
between the APOE  and  LIPC  genes. Nonetheless, the
results do suggest a modification in TAG metabolism
within the HGI relative to the NGI group that is likely
associated with their glycemic and insulinemic dysfunc-
tion.
The current study has both limitations and strengths
that deserve mention. Although the consideration of
genetic variation strengthened the current study, there
was a limited ability to detect genotype-treatment inter-
actions due to under-representation of the rare APOE
and  LIPC  polymorphisms. This under-representation
was in part due to retrospective genotyping, which
although common due to the financial and labour con-
straints, causes further reason to interpret the results
with caution. Also worth noting as a limitation is tha t
particle size was not measured for either of the treatment
breads. Strengths of the study include its randomized
crossover design, and inclusion of not only the polymor-
phisms, but 2 participant groups of distinct CVD risk.
Also, the study participants maintained their usual diet
and since they were provided with the treatment bread,
they were not required to self-select their whole grain
products, which may help to minimize potential con-
founding variables. Furthermore the direct comparison of
whole grain wheat to refined wheat bread adds clarity to
the wheat literature in ascertaining the difference in
health effects between whole grain and refined foods.
Conclusions
In summary, this study uniquely compared whole grain
wheat to refined wheat bread and considered the influ-
ence of individual CVD risk and genetic variation on
serum lipid response. Participants were not counselled on
the macronutrient distribution of their diet and their
intake was comparable to that reported in Canadian
nutrition surveys [43]. Results showed that 6-week con-
sumption of whole grain wheat sourdough bread did not
significantly affect serum lipids in comparison to white
bread, in adults of either a low or high level of CVD risk.
When genetic variation was considered, albeit limited by
retrospective assessment, it was found that in those with
the APOE E3/E3 genotype, whole grain wheat sourdough
bread unfavourably increased LDL-cholesterol in NGI
participants, and TAG and TAG:HDL-cholesterol in HGI
participants, when compared to white bread. These data
add to the limited literature of intervention studies exam-
ining whole grain wheat relative to refined wheat breads
and emphasize the need to consider genetic variation in
relation to lipoprotein lipid content and CVD risk.
List of abbreviations
ANCOVA: analysis of covariance; CFG: Canada's Food
Guide;  CVD: cardiovascular disease; g·L-1: grams per
liter;  LIPC: hepatic lipase gene promoter; HOMA-IR:
homeostasis model assessment of insulin resistance;
HGI: hyperglycemic/hyperinsulinemic; mmol·L-1: milli-
moles per liter; ng·L-1: nanograms per liter; NGI: normo-
glycemic/normoinsulinemic;  pmol·L-1: picomoles per
liter; SNP: single-nucleotide polymorphism.
HGI 1.40 ± 0.09 1.44 ± 0.08 1.41 ± 0.07 1.47 ± 0.08 0.74
Apolipoprotein B:Apolipoprotein AI
NGI 0.63 ± 0.08 0.65 ± 0.08 0.67 ± 0.08 0.64 ± 0.07 0.08
HGI 0.74 ± 0.09 0.76 ± 0.08 0.73 ± 0.07 0.72 ± 0.08 0.18
1Values are mean ± SEM unless otherwise indicated. Abbreviations: chol: cholesterol.
2P-value for treatment effect comparison between day 43 values of white and whole grain sourdough breads within the NGI and HGI groups, 
using repeated measures ANCOVA controlling for participant, treatment period and treatment and including d 1 values as a covariate, 
followed by the Tukey's test for multiple comparisons.
3Within the HGI group, n = 8 for whole grain wheat sourdough bread (Days 1 and 43) and n = 9 for white bread (Days 1 and 43).
4Data were log-transformed prior to statistical analysis and presented as geometric mean (95% CI).
Table 5: Effect of 6-wk whole grain whole wheat sourdough bread consumption on fasting serum lipids in NGI and HGI 
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